Australian Clinical Labs Limited Recently Missed Earnings, Prompting Analysts to Revise Their Models

2 min read | March 03, 2025 01:39 PM AEDT | By Team Kalkine Media

Google News:

Australian Clinical Labs Limited Recently Missed Earnings, Prompting Analysts to Revise Their Models — Image source: Shutterstock

Recent News

Zip Shares Push Higher as Market Watches Key Turning Point

Could These Under-the-Radar ASX Stocks Be Worth Watching?

ASX 200 Soars as Trump Signals Surprise Iran Peace Shift

Which ASX Small Caps Are Making Early Moves Today?

Make Kalkine Media
My Trusted Source

Highlights

Australian Clinical Labs reports mixed results with revenue exceeding estimates.

Analysts adjust earnings expectations amidst market uncertainties.

Revenue growth projected to align with industry standards.

Australian Clinical Labs Limited (ASX:ACL) experienced a challenging week as its stock price decreased by 16%, settling at AU$3.10. This drop followed the release of the company's recent half-yearly results, which revealed that while revenues of AU$370m exceeded forecasts by 4%, earnings per share fell short by 22%, landing at AU$0.058 per share.

Analysts have revised their forecasts in light of these results, offering insights on expected performance for 2025. The updated consensus among eight analysts is for Australian Clinical Labs to achieve revenues of AU$747.0m, marking a 2.6% increase from the past year's figures. Additionally, earnings are projected to rise by 15%, reaching AU$0.18 per share, although this is a slight downgrade from previous estimates of AU$0.19 per share.

Despite the adjustments in earnings expectations, experts have kept the consensus price target relatively stable at AU$3.81. This suggests that analysts do not foresee the recent earnings shortfall significantly affecting the company's overall valuation. The forecast range varies, with the most optimistic projections placing the stock at AU$5.00, while the most conservative expect AU$3.15 per share, indicating diverse perspectives on the company's future.

When evaluating Australian Clinical Labs' forecasts, it's noteworthy that the company is expected to outpace its historical performance, with revenues anticipated to grow 5.2% annually until the end of 2025. This contrasts with a 12% decline over the past three years. However, the projected growth aligns closely with the overall industry's expected annual growth rate of 6.1%.

Looking ahead, analysts express concerns over potential business challenges reflected in the adjusted earnings expectations. The company is predicted to expand its revenues at a pace comparable to the broader industry, reinforcing the stability in its market position. The intrinsic value of the business appears consistent with previous estimates, with no significant alterations to the consensus price target.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.